A carregar...

Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme

Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an imm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Xu, Xun, Stockhammer, Florian, Schmitt, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3299309/
https://ncbi.nlm.nih.gov/pubmed/22474481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/764213
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!